- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03028961
Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant (BMTSLPRCT)
Randomized Clinical Study Comparing the Effectiveness of the Stanford Letter to the Traditional Advance Directive in Bone Marrow Transplant Recipients
The purpose of the proposed research study is to evaluate whether bone marrow transplant patients prefer the Stanford letter advance care planning tool to the standard Advance directive.
Completion of advance care planning prior to BMT is very important, but not often done. The investigators believe that the Stanford Letter will be preferred by patients and will allow them to feel more comfortable and share more of their wishes with family members and the medical team.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
PRIMARY OBJECTIVES I. To compare advance care planning (ACP) completion rate amongst bone marrow transplant (BMT) recipients receiving the Stanford Letter versus the traditional advance directive (AD) through a prospective, pilot randomized controlled trial (RCT).
SECONDARY OBJECTIVES:
I. To evaluate differences in patient preference for choice to prolong life following completion of the ACP tool in each group.
II. To assess uncertainty with decision making regarding end of life care following completion of the ACP tool in each group.
III. To explore patient understanding of and satisfaction with the ACP tool in each group.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
GROUP II (CONTROL): Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the California (CA) Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
After completion of study, patients are followed up periodically.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Palo Alto, California, Vereinigte Staaten, 94304
- Stanford University, School of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- All BMT patients at Stanford who are adults and give consent
Exclusion Criteria:
- Less than 18 years of age
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group I (Stanford Letter, interview)
Patients listen to a dialogue on the purpose of ACP.
Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT.
After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
|
Nebenstudien
Receive and complete the Stanford Letter
Andere Namen:
Undergo semi-structured, research staff-led interview
|
Aktiver Komparator: Group II (traditional advance directive, interview)
Patients listen to a dialogue on the purpose of ACP.
Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT.
After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
|
Nebenstudien
Undergo semi-structured, research staff-led interview
Receive and complete the CA Advance Health Care Directive Form
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
ACP completion rate defined as a completed Advance Directive tool (either Stanford Letter or standard CA AD) brought to Stanford University for upload into the medical record
Zeitfenster: Up to BMT day 0
|
The chi-square (X^2) test will be used to determine a significant difference in proportion of ACP tool completion and preferences for choice to prolong life between the two groups.
|
Up to BMT day 0
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Patient preferences for life sustaining measures measured via answers to the ACP questions related to use of cardiopulmonary resuscitation and use of mechanical intubation
Zeitfenster: Up to BMT day 0
|
The X^2 test will be used to determine a significant difference in proportion of ACP tool completion and preferences for choice to prolong life between the two groups.
|
Up to BMT day 0
|
Uncertainty with decision making regarding end of life care measured related to the Decisional Conflict Scale (DCS) results
Zeitfenster: Up to BMT day 0
|
Will be measured using the DCS uncertainty sub-scale (score 0-15; higher score indicates greater uncertainty).
Scores from each group will be compared by t-tests.
|
Up to BMT day 0
|
Understanding of the ACP tool measured using qualitative and quantitative data obtained through the semi-structured interview and DCS
Zeitfenster: within 28 days of ACP completion
|
Will be measured using the DCS effective decision-making sub-scale (score 0-15; higher scores indicate 6 less effective decision-making).
Likert scores of understanding of the ACP from each group will be summarized and compared by t-tests.
|
within 28 days of ACP completion
|
Satisfaction with the ACP tool measured using qualitative and quantitative data obtained through the semi-structured interview and DCS
Zeitfenster: within 28 days of ACP completion
|
Will be measured using the DCS effective decision-making sub-scale (score 0-15; higher scores indicate 6 less effective decision-making).
Scores from each group will be compared by t-tests.
Likert scores of satisfaction with the ACP will be summarized and compared by group using t-tests.
|
within 28 days of ACP completion
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lori Muffly, MD, Stanford Cancer Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- BMT313
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Knochenmarktransplantation
-
Baylor College of MedicinePatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; The... und andere MitarbeiterAbgeschlossenHerzinsuffizienz im Endstadium | Bridge-to-Transplant-LVAD-Platzierung (BTT) | Destination Therapy LVAD-Platzierung (DT) | Ablehnung der LVAD-Platzierung (Ablehner) | LVAD-BetreuerVereinigte Staaten
-
University Hospital FreiburgAbgeschlossenMyelodysplastische Syndrome | Fanconi-Anämie | Dyskeratosis congenita | Pearson Marrow-Pankreas-Syndrom | Shwachman-Diamond-SyndromSpanien, Deutschland, Schweiz, Österreich, Niederlande, Italien, Tschechische Republik, Belgien, Dänemark, Irland
Klinische Studien zur Fragebogenverwaltung
-
Centre for Research and Technology HellasRekrutierungMyelodysplastische Syndrome | Chronischer lymphatischer LeukämieItalien
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenGesundKorea, Republik von
-
Catholic University of the Sacred HeartAbgeschlossenLebensqualität | Chirurgische Wunde | Biopsie-Wunde | Heilung von OperationswundenItalien
-
Daewoong Pharmaceutical Co. LTD.Unbekannt
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenStudie zur Arzneimittelinteraktion zwischen DWC20155/DWC20156 und DWC20161 bei gesunden FreiwilligenGesundKorea, Republik von
-
Fondazione Poliambulanza Istituto OspedalieroUnbekanntMedikationsfehler und andere Fehler und Probleme bei der Produktverwendung | Unerwünschtes ArzneimittelereignisItalien
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Stanford University und andere MitarbeiterNoch keine RekrutierungMalaria | Malaria, VivaxPeru
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA); Johns Hopkins University; NYU Langone... und andere MitarbeiterAbgeschlossenSubstanzgebrauchsstörungVereinigte Staaten
-
Wayne State UniversityUnbekanntOpioidabhängigkeit | Opioidgebrauch | KnochenbruchVereinigte Staaten
-
Clinique Romande de ReadaptationRekrutierungHandverletzungen und -erkrankungenSchweiz